MA26960A1 - Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation - Google Patents

Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation

Info

Publication number
MA26960A1
MA26960A1 MA27158A MA27158A MA26960A1 MA 26960 A1 MA26960 A1 MA 26960A1 MA 27158 A MA27158 A MA 27158A MA 27158 A MA27158 A MA 27158A MA 26960 A1 MA26960 A1 MA 26960A1
Authority
MA
Morocco
Prior art keywords
salts
hemi
isothiazole
formula
carboxamide
Prior art date
Application number
MA27158A
Other languages
English (en)
Inventor
Thomas G Gant
Glenn Robert Williams
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26960A1 publication Critical patent/MA26960A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 28 Novembre 2000 60/253,513 Voir en annexe le titre de l'invention et le texte de l'abrégé Sels d'un isothiazole-4-carboxamide et leur utilisation comme agents anti-hyperprolifération chlorhydrate, bromhydrate, hémi-citrate, acétate, p-tosy-late, L-tartrate, hémi-succinate et mésylate d'amide d'acide 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrroli-dine-1-yle-butyl)-uréido]-isothiazole-4-carboxylique répondant à la formule suivante : formule 1. La présente invention concerne également des compositions pharmaceutiques contenant les sels consistant en chlorhydrate, bromhydrate, hémi-citrate, acétate, p-tosylate, L-tartrate, hémi-succinate et mésylate du composé de formule 1. L'invention concerne en outre des méthodes de traitement de maladies hyperprolifératives, telles que des cancers, chez des mammifères, notamment chez l'homme, en administrant les sels précités, et des procédés pour la préparation des formes cristallines des sels précités.
MA27158A 2000-11-28 2003-05-13 Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation MA26960A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25351300P 2000-11-28 2000-11-28

Publications (1)

Publication Number Publication Date
MA26960A1 true MA26960A1 (fr) 2004-12-20

Family

ID=22960587

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27158A MA26960A1 (fr) 2000-11-28 2003-05-13 Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation

Country Status (49)

Country Link
US (1) US6831091B2 (fr)
EP (1) EP1337521B1 (fr)
JP (2) JP2004514714A (fr)
KR (2) KR20050116401A (fr)
CN (1) CN1231474C (fr)
AP (1) AP2001002358A0 (fr)
AR (1) AR031512A1 (fr)
AT (1) ATE340786T1 (fr)
AU (2) AU1420402A (fr)
BG (1) BG107752A (fr)
BR (1) BR0115621A (fr)
CA (1) CA2430065C (fr)
CR (1) CR6963A (fr)
CY (1) CY1106240T1 (fr)
CZ (1) CZ20031315A3 (fr)
DE (1) DE60123461T2 (fr)
DK (1) DK1337521T3 (fr)
DO (1) DOP2001000288A (fr)
EA (1) EA005859B1 (fr)
EC (1) ECSP034628A (fr)
EE (1) EE200300247A (fr)
ES (1) ES2271086T3 (fr)
GE (1) GEP20053652B (fr)
GT (1) GT200100237A (fr)
HN (1) HN2001000268A (fr)
HR (1) HRP20030408A2 (fr)
HU (1) HUP0302553A3 (fr)
IL (1) IL155371A0 (fr)
IS (1) IS6788A (fr)
MA (1) MA26960A1 (fr)
MX (1) MXPA03004714A (fr)
MY (1) MY136686A (fr)
NO (1) NO325187B1 (fr)
NZ (1) NZ525788A (fr)
OA (1) OA12532A (fr)
PA (1) PA8533801A1 (fr)
PE (1) PE20020591A1 (fr)
PL (1) PL362079A1 (fr)
PT (1) PT1337521E (fr)
SI (1) SI1337521T1 (fr)
SK (1) SK5862003A3 (fr)
SV (1) SV2002000748A (fr)
TN (1) TNSN01167A1 (fr)
TW (1) TWI287542B (fr)
UA (1) UA74221C2 (fr)
UY (1) UY27039A1 (fr)
WO (1) WO2002044158A1 (fr)
YU (1) YU36403A (fr)
ZA (1) ZA200303341B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (fr) 1999-01-13 2013-10-08 Bayer Healthcare Llc Diphenyle urees a substitution .omega.-carboxy aryle en tant qu'inhibiteurs de la kinase p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2324825A1 (fr) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylurées dotées d'une activité d'inhibition de l'angiogenèse
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
AU2003281664A1 (en) * 2002-07-25 2004-02-16 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
EP1545519B1 (fr) * 2002-08-19 2011-03-23 Pfizer Inc. Therapie de combinaison pour maladies hyperproliferatives
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
AU2004287416C1 (en) * 2003-10-27 2010-09-09 Merck Sharp & Dohme Corp. CCR-2 antagonist salt
WO2005061519A1 (fr) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Inhibiteurs de kinase
WO2005102327A1 (fr) * 2004-04-20 2005-11-03 Pfizer Products Inc. Formes posologiques et procedes de traitement utilisant des inhibiteurs vegfr
JP2007535565A (ja) 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR101627901B1 (ko) 2006-06-16 2016-06-13 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2011073521A1 (fr) 2009-12-15 2011-06-23 Petri Salven Méthodes pour l'enrichissement de cellules progénitrices endothéliales adultes et leurs utilisations
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
KR102433489B1 (ko) * 2013-03-14 2022-08-17 팬옵티카, 인크. 눈의 후안부로의 약물 전달을 위한 안구용 제제
ES2863601T3 (es) * 2014-09-17 2021-10-11 Panoptica Inc Formulaciones oculares para administración de fármacos y protección del segmento anterior del ojo
TWI894754B (zh) * 2022-12-28 2025-08-21 大陸商蘇州必揚醫藥科技有限公司 一種蛋白酪胺酸激酶抑制劑及其醫藥用途
WO2026002133A1 (fr) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 Forme saline d'un inhibiteur de protéine tyrosine kinase
WO2026002142A1 (fr) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 Forme cristalline d'hémisuccinate d'inhibiteur de protéine tyrosine kinase
WO2026002126A1 (fr) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 Inhibiteur de protéine tyrosine kinase et préparation ophtalmique associée

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
SI1337521T1 (sl) 2006-12-31
MY136686A (en) 2008-11-28
UY27039A1 (es) 2002-07-31
SV2002000748A (es) 2002-12-02
PA8533801A1 (es) 2002-10-31
HRP20030408A2 (en) 2003-08-31
JP4971946B2 (ja) 2012-07-11
CY1106240T1 (el) 2011-06-08
EE200300247A (et) 2003-10-15
ATE340786T1 (de) 2006-10-15
GT200100237A (es) 2002-07-03
AU2002214204B2 (en) 2007-05-24
CN1231474C (zh) 2005-12-14
NO20032388L (no) 2003-07-18
JP2004514714A (ja) 2004-05-20
AU1420402A (en) 2002-06-11
EP1337521B1 (fr) 2006-09-27
DK1337521T3 (da) 2007-01-29
DE60123461T2 (de) 2007-02-15
KR20050116401A (ko) 2005-12-12
PL362079A1 (en) 2004-10-18
EA005859B1 (ru) 2005-06-30
HUP0302553A2 (hu) 2003-11-28
CR6963A (es) 2003-11-25
HK1059085A1 (en) 2004-06-18
EA200300424A1 (ru) 2003-10-30
EP1337521A1 (fr) 2003-08-27
NO20032388D0 (no) 2003-05-27
DE60123461D1 (de) 2006-11-09
TWI287542B (en) 2007-10-01
BG107752A (bg) 2004-01-30
YU36403A (sh) 2006-08-17
US20020151573A1 (en) 2002-10-17
NZ525788A (en) 2004-11-26
GEP20053652B (en) 2005-11-10
CN1476439A (zh) 2004-02-18
CZ20031315A3 (cs) 2004-04-14
IS6788A (is) 2003-04-14
CA2430065A1 (fr) 2002-06-06
BR0115621A (pt) 2003-09-02
US6831091B2 (en) 2004-12-14
HN2001000268A (es) 2002-01-30
CA2430065C (fr) 2008-05-20
AR031512A1 (es) 2003-09-24
NO325187B1 (no) 2008-02-11
OA12532A (en) 2006-06-02
ES2271086T3 (es) 2007-04-16
HUP0302553A3 (en) 2009-03-30
PE20020591A1 (es) 2002-07-06
PT1337521E (pt) 2006-12-29
TNSN01167A1 (fr) 2005-11-10
ECSP034628A (es) 2003-07-25
AP2001002358A0 (en) 2001-12-31
IL155371A0 (en) 2003-11-23
SK5862003A3 (en) 2004-05-04
UA74221C2 (uk) 2005-11-15
WO2002044158A1 (fr) 2002-06-06
JP2008056692A (ja) 2008-03-13
DOP2001000288A (es) 2002-12-15
ZA200303341B (en) 2004-04-30
MXPA03004714A (es) 2003-08-19
KR20030059275A (ko) 2003-07-07

Similar Documents

Publication Publication Date Title
MA27095A1 (fr) Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
CA2430065A1 (fr) Sels d'un isothiazole-4-carboxamide et leur utilisation comme agents anti-hyperproliferatifs
WO2001085257A3 (fr) Compositions d'antagoniste opioide et formes de dosage
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
MA27385A1 (fr) Therapie combinee de maladies hyperproliferatives.
TR200100889T2 (tr) Disfosfonik asit içeren terkipler
HUP0301972A2 (hu) Fentanilszerű szerkezetű opioidot és ketamint tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
TNSN00231A1 (fr) Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
TR199700878T1 (xx) Monamin oksidaz B inhibit�rleri i�eren farmakotik kompozisyonlar.
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
MA70477B1 (fr) Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
MA29950B1 (fr) Nouveau derive de la pleuromutiline et son utilisation
WO1997035574A1 (fr) Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
CA2357114A1 (fr) Utilisation de melatonine dans la fabrication d'un medicament pour traiter l'hyperactivite avec deficit de l'attention
PT1121109E (pt) Formulacao bifasica contendo tramadol
JPH02502545A (ja) 抗ひきつけ剤組成物および方法のためのデキストロメトルファン相乗的協力剤